The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Open accessAbstract
During carcinogenesis of pancreatic islets in transgenic mice, an angiogenic switch activates the quiescent vasculature. Paradoxically, vascular endothelial growth factor (VEGF) and its receptors are expressed constitutively. Nevertheless, a synthetic inhibitor (SU5416) of VEGF signalling impairs angiogenic switching and tumour growth. Two metalloproteinases, MMP-2/gelatinase-A and MMP-9/gelatinase-B, are upregulated in angiogenic lesions. MMP-9 can render normal islets angiogenic, releasing VEGF. MMP inhibitors reduce angiogenic switching, and tumour number and growth, as does genetic ablation of MMP-9. Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
From Inflammation and cancer (2002) · cites this paper as [26]
In the citing paper
“Furthermore, the actions of MMP-9 both break down the fibrous collagen matrix to make space for new blood vessels and release matrix-bound VEGF (53).”
From The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. (2017) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,162
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O’Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,661
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., & Ferrara, N. (1999) · Nature Medicine · doi:10.1038/9467 · Cited by 2,107
Self-citationYu, Q., & Stamenkovic, I. (2000) · PubMed · Cited by 1,952
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Self-citationYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Cited by
Sorted by citations
Items 801–900 of 1,009
Kunigal, S., Lakka, S. S., Gondi, C. S., Estes, N. C., & Rao, J. S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22962 · Cited by 85
RetractedKenig, S., Alonso, M. B. D., Mueller, M. M., & Lah, T. T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.07.014 · Cited by 84
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
Reardon, D. A., Wen, P. Y., Desjardins, A., Batchelor, T. T., & Vredenburgh, J. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.541 · Cited by 87
Owen, J. L., Iragavarapu‐Charyulu, V., Gunja‐Smith, Z., Herbert, L. M., Grosso, J. F., & Lopez, D. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4340 · Cited by 85
Fibronectin Deposition Participates in Extracellular Matrix Assembly and Vascular Morphogenesis
Hielscher, A. C., Ellis, K., Qiu, C. C., Porterfield, J., & Gerecht, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147600 · Cited by 84
Metalloproteinases and their roles in human cancer
Roy, R., Morad, G., Jedinak, A., & Moses, M. A. (2019) · The Anatomical Record · doi:10.1002/ar.24188 · Cited by 84
“, 2008) and angiogenic mitogens such as VEGF (Bergers et al., 2000; Hawinkels et al., 2008; Romagnoli et al., 2014) and bFGF (Whitelock et al.”
BackgroundXu, M., Su, T., Jin, X., Li, Y., Yao, Y., Liu, K., Chen, K., Lu, F., & He, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.015 · Cited by 86
Expression and quantitative analysis of matrix metalloproteinase-2 and-9 in human gliomas
Komatsu, K., Nakanishi, Y., Nemoto, N., Hori, T., Sawada, T., & Kobayashi, M. (2004) · Brain Tumor Pathology · doi:10.1007/bf02482184 · Cited by 84
Perez‐Gracia, J. L., Prior, C., Guillén‐Grima, F., Segura, V., González, Á., Panizo, Á., Melero, I., Grande-Pulido, E., Gúrpide, A., Bazo, I. G., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605409 · Cited by 84
von Burstin, J., Eser, S., Seidler, B., Meining, A. G., Bajbouj, M., Mages, J., Lang, R., Kind, A., Schnieke, A., Schmid, R. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23780 · Cited by 84
Recruitment and retention: factors that affect pericyte migration
Aguilera, K. Y., & Brekken, R. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1432-z · Cited by 83
Self-citationRyschich, E., Lizdenis, P., Ittrich, C., Benner, A., Stahl, S. H., Hamann, A., Schmidt, J., Knolle, P. A., Arnold, B., Hämmerling, G. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1636 · Cited by 84
Wartenberg, M., Budde, P., de Marées, M., Grünheck, F., Tsang, S. Y., Huang, Y., Chen, Z., Hescheler, J., & Sauer, H. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000049348.51663.2f · Cited by 83
The interplay between innate and adaptive immunity regulates cancer development
de Visser, K. E., & Coussens, L. M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0702-5 · Cited by 83
MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2
Yang, F., Wang, W., Zhou, C., Xi, W., Lu, Y., Chen, X., Li, Y., Yang, A., Zhang, J., & Wang, T. (2015) · Tumor Biology · doi:10.1007/s13277-014-3017-3 · Cited by 85
“On one hand, because MMPs, such as MMP-2 and MMP-9 which are mostly reported to play a role in human glioma progression [35], can promote endothelial cell migration and trigger an angiogenic switch by releasing vascular VEGF from the extracellular matrix [36, 37], the inhibition of MMPs accounts for a major part of th…”
BackgroundInhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum
Nangia‐Makker, P., Tait, L. R., Shekhar, M. P. V., Palomino, E., Hogan, V. A., Piechocki, M. P., Funasaka, T., & Raz, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22733 · Cited by 87
Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment
Chavakis, T., Athanasopoulos, A. N., Rhee, J.-S., Orlova, V. V., Schmidt-Wöll, T., Bierhaus, A., May, A. E., Çeli̇k, İ., Nawroth, P. P., & Preissner, K. T. (2004) · Blood · doi:10.1182/blood-2004-01-0166 · Cited by 83
Pittoni, P., Piconese, S., Tripodo, C., & Colombo, M. P. (2010) · Oncogene · doi:10.1038/onc.2010.494 · Cited by 85
Yamakawa, S., Asai, T., Uchida, T., Matsukawa, M., Akizawa, T., & Oku, N. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.03.008 · Cited by 83
Taguchi, A., Kawana, K., Tomio, K., Yamashita, A., Isobe, Y., Nagasaka, K., Koga, K., Inoue, T., Nishida, H., Kojima, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089605 · Cited by 84
“MMP inhibitors reduce angiogenesis, tumor number, and tumor growth, as does genetic ablation of MMP-9 [38].”
Interaction of angiogenic microvessels with the extracellular matrix
Krishnan, L., Hoying, J. B., Nguyen, H. T., Song, H., & Weiss, J. A. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00772.2007 · Cited by 83
Shin, S. Y., Kim, J. H., Baker, A. H., Lim, Y., & Lee, Y. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0454 · Cited by 83
A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer
Miller, K. D., Saphner, T. J., Waterhouse, D. M., Chen, T., Rush-Taylor, A., Sparano, J. A., Wolff, A. C., Cobleigh, M., Galbraith, S. M., & Sledge, G. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0968 · Cited by 83
Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo
Jung, S.-K., Lee, K. W., Byun, S., Lee, E. J., Kim, J. E., Bode, A. M., Dong, Z., & Lee, H. J. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp221 · Cited by 83
Matrix metalloproteinases and cellular motility in development and disease
VanSaun, M. N., & Matrisian, L. M. (2006) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20061 · Cited by 83
Andreuzzi, E., Colladel, R., Pellicani, R., Tarticchio, G., Cannizzaro, R., Spessotto, P., Bussolati, B., Brossa, A., Paoli, P. D., Canzonieri, V., et al. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.04.002 · Cited by 82
RetractedHe, W., Wang, S., Yan, J., Qu, Y., Jin, L., Sui, F., Li, Y., You, W., Yang, G., Yang, Q., et al. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201807736 · Cited by 82
ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis
Lambert, J., Makin, K. A., Akbareian, S. E., Johnson, R. T., Alghamdi, A. A. A., Robinson, S. D., & Edwards, D. R. (2020) · Journal of Cell Science · doi:10.1242/jcs.235762 · Cited by 82
“However, as well as its proteolytic function, ADAMTS-1 also interacts with other proteins including latent TGF-β(Bourd-Boittin et al., 2011) and fibulin-1, which acts as a co-factor(Lee et al., 2005).”
BackgroundRennie, M. Y., Detmar, J., Whiteley, K. J., Yang, J., Jurisicova, A., Adamson, S. L., & Sled, J. G. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00510.2010 · Cited by 87
A functional role of gelatinase A in the development of nutritionally induced obesity in mice
Hul, M. V., & LIJNEN, H. R. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02988.x · Cited by 81
Technologically advanced cancer modeling in mice
Tuveson, D. A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00272-6 · Cited by 80
Lakka, S. S., Gondi, C. S., Yanamandra, N., Dinh, D. H., Olivero, W. C., Gujrati, M., & Rao, J. S. (2003) · PubMed · Cited by 82
Prior, C., Perez‐Gracia, J. L., García-Donás, J., Rodríguez‐Antona, C., Guruceaga, E., Esteban, E., Suárez, C., Castellano, D., del Alba, A. G., Lozano, M. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086263 · Cited by 82
“[30].”
Chiba, M., Kubota, S., Sato, K., & Monzen, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30446-1 · Cited by 82
Yan, H. H., Jiang, J. D., Pang, Y., Achyut, B. R., Lizardo, M. M., Liang, X., Hunter, K. W., Khanna, C., Hollander, C. M., & Li, Y. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2282-t · Cited by 83
“Pro-MMP9, a key regulator for tumor vascular remodeling (35), was also expressed in these myeloid cells (Fig.”
MT-MMPS as Regulators of Vessel Stability Associated with Angiogenesis
Sounni, N. E., Paye, A., Host, L., & Noël, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00111 · Cited by 82
Overexpression of MMP-9 Contributes to Invasiveness of Prostate Cancer Cell Line LNCaP
Aalinkeel, R., Nair, B. B., Reynolds, J. L., Sykes, D. E., Mahajan, S. D., Chadha, K. C., & Schwartz, S. A. (2011) · Immunological Investigations · doi:10.3109/08820139.2011.557795 · Cited by 81
Monaco, S., Sparano, V., Gioia, M., Sbardella, D., Pierro, D. D., Marini, S., & Coletta, M. (2006) · Protein Science · doi:10.1110/ps.062430706 · Cited by 81
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
Yang, F., Lee, G., & Fan, Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09913-z · Cited by 90
Xie, Y., Wang, X., Wang, W., Pu, N., & Liu, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06422-5 · Cited by 80
“In pancreatic neuroendocrine tumors, MMP-9 can free VEGF from the matrix, thereby triggering angiogenesis and further promoting tumor growth and spread [138].”
Zhao, H., Yang, Z., Wang, X., Zhang, X., Wang, M., Wang, Y., Mei, Q., & Wang, Z. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.11.072 · Cited by 81
Grippo, P. J., Fitchev, P. S., Bentrem, D. J., Melstrom, L. G., Dangi-Garimella, S. Y., Krantz, S. B., Heiferman, M. J., Chung, C., Adrián, K., Cornwell, M. L., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300821 · Cited by 79
Houben, A., Kostanova‐Poliakova, D., Weißenböck, M., Graf, J., Teufel, S., von der Mark, K., & Hartmann, C. (2016) · Development · doi:10.1242/dev.137489 · Cited by 83
“5, or the liberation of matrix-bound VEGF due to increased osteoclastic activity at the chondro-osseous front (Bergers et al., 2000; Huang et al., 2002).”
BackgroundMast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski, M., Bauer, R., Cubas‐Cordova, M., Udonta, F., Batalla, I. B., Legler, K., Hauser, C., Egberts, J. H., Janning, M., Velthaus, J.-L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00327-8 · Cited by 80
TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association
Zonneville, J., Safina, A. F., Truskinovsky, A. M., Arteaga, C. L., & Bakin, A. V. (2018) · BMC Cancer · doi:10.1186/s12885-018-4587-z · Cited by 82
“Pro-angiogenic activity of myeloid cells depends on metalloproteinase MMP9/gelatinase-B [5–7], which releases VEGFA from matrix-deposited sources increasing recruitment of endothelial cells and pericytes [6, 8].”
BackgroundMetalloproteinases in Ovarian Cancer
Carey, P. M., Low, E. L., Harper, E. I., & Stack, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073403 · Cited by 85
“it tr ils, hich expres MMP-9, which encourages VEGF production in a posit ve feedback loop [92,93].”
BackgroundRise of the natural red pigment ‘prodigiosin’ as an immunomodulator in cancer
Anwar, M. M., Albanese, C., Hamdy, N. Μ., & Sultan, A. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02815-4 · Cited by 81
Cochain, C., Rodero, M. P., Vilar, J., Récalde, A., Richart, A. L., Loinard, C., Zouggari, Y., Guérin, C. L., Duriez, M., Combadière, B., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq153 · Cited by 85
The Extracellular Matrix Protein 1: Its Molecular Interaction and Implication in Tumor Progression
Sercu, S., Zhang, L., & Merregaert, J. (2008) · Cancer Investigation · doi:10.1080/07357900701788148 · Cited by 79
Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Seo, J. H., Guo, S., Lok, J. M., Navaratna, D., Whalen, M. J., Kim, K., & Lo, E. H. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802002742 · Cited by 80
Cominelli, A., Chevronnay, H. P. G., Lemoine, P., Courtoy, P. J., Marbaix, É., & Henriet, P. (2014) · Molecular Human Reproduction · doi:10.1093/molehr/gau034 · Cited by 79
“MMPs could also promote endometriosis development by promoting the maturation and/or release of angiogenic factors such as interleukin-8, vascular endothelial growth factor and transforming growth factor-β (Van den Steen et al., 2000; Colnot et al., 2003; Bergers et al., 2000; Lee et al., 2005).”
BackgroundBuilding ‘validated’ mouse models of human cancer
Hann, B. C., & Balmain, A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00283-0 · Cited by 76
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression
Sieuwerts, A. M., Vries, J. B.-D., Bosma, P. T., Swiggers, S. J. J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613457 · Cited by 79
Integrin Regulation of Epidermal Functions in Wounds
Longmate, W. M., & DiPersio, C. M. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0516 · Cited by 78
“, VEGF) to promote angiogenesis.(151,152) In addition, degradation of laminins, collagens, or other ECM proteins by some of these extracellular proteases may lead to the generation of bioactive matrix fragments that can directly stimulate cell growth or motility.”
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79
“(TAMs) facilitate tumor growth and progression through the production of proteases and angiogenic factors [13,14].”
BackgroundRetractedLee, H., Park, D., & Yoon, M. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.11.052 · Cited by 78
Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases
Dakroub, A. H., Nasser, S. A., Kobeissy, F. H., Yassine, H. M., Orekhov, A. N., Sharifi‐Rad, J., Iratni, R., EL‐Yazbi, A. F., & Eid, A. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30345 · Cited by 80
“MMP‐9 processing is required to mobilize VEGF to its receptor, where it can bind and in- itiate angiogenesis (Bergers et al., 2000).”
BackgroundInfluentialMechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 90
“MMP-9, which controls the switch for angiogenesis by releasing VEGF from its membrane-bound form, has been shown to be expressed in myeloid cells (98).”
BackgroundRunx2 in human breast carcinoma: its potential roles in cancer progression
Onodera, Y., Miki, Y., Suzuki, T., Takagi, K., Akahira, J., Sakyu, T., Watanabe, M., Inoue, S., Ishida, T., Ohuchi, N., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01742.x · Cited by 78
Gene Transfer of Matrix Metalloproteinase-9 Induces Tumor Regression of Breast CancerIn vivo
Bendrik, C., Robertson, J. V., Gauldie, J., & Dabrosin, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0295 · Cited by 78
Primo, L., Seano, G., Roca, C., Maione, F., Gagliardi, P. A., Sessa, R., Martinelli, M., Giraudo, E., di Blasio, L., & Bussolino, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0507 · Cited by 78
Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis
Haxho, F., Neufeld, R. J., & Szewczuk, M. R. (2016) · Oncotarget · doi:10.18632/oncotarget.8396 · Cited by 78
“Moreover, MMP9 has been shown to trigger the angiogenic switch during carcinogenesis [203].”
BackgroundExpression of Matrix Metalloproteinases in Human Breast Cancer Tissues
Selvanesan, B. C., Babu, S. D., Selvi, R., Selvamurugan, N., & Sankar, B. R. (2013) · Disease Markers · doi:10.1155/2013/420914 · Cited by 78
Stromal Cell Involvement in Cancer
Almholt, K., & Johnsen, M. (2003) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59349-9_3 · Cited by 78
Ramucirumab (IMC-1121B): A Novel Attack on Angiogenesis
Spratlin, J. L., Mulder, K. E., & Mackey, J. R. (2010) · Future Oncology · doi:10.2217/fon.10.75 · Cited by 76
Chimal-Ramírez, G. K., Espinoza‐Sánchez, N. A., & Fuentes‐Pananá, E. M. (2013) · Journal of Oncology · doi:10.1155/2013/835956 · Cited by 80
Jakubowska, K., Pryczynicz, A., Januszewska, J., Sidorkiewicz, I., Kemonä, A., Niewiński, A., Lewczuk, Ł., Kędra, B., & Guzińska-Ustymowicz, K. (2016) · Disease Markers · doi:10.1155/2016/9895721 · Cited by 77
“MMP-9 is considered to be a strong factor stimulating the secretion of proangiogenic factors, such as vascular endothelial growth factor (VEGF) which participates in the new blood vessel formation [26, 27].”
BackgroundThe effect of statins on survival in patients with stage IV lung cancer
Lin, J. J., Ezer, N., Sigel, K. M., Mhango, G., & Wisnivesky, J. P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.006 · Cited by 77
Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects
Sternlicht, M. D., & Bergers, G. (2000) · Emerging Therapeutic Targets · doi:10.1517/14728222.4.5.609 · Cited by 76
Self-citationTumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 82
“Indeed, this neutrophildependent mechanism was critical to instigate the angiogenic switch in the dysplastic stage of pancreatic islets in the Rip1Tag2 endogenous pancreatic neuroendocrine tumor model because not only MMP-9 inhibition but also neutrophil depletion was sufficient to diminish the angiogenic switch (73,…”
BackgroundSelf-citationRational targeting of immunosuppressive neutrophils in cancer
Zhao, Y., Rahmy, S., Liu, Z., Zhang, C., & Lü, X. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107556 · Cited by 78
Onoue, S., Kobayashi, T., Takemoto, Y., Sasaki, I., & Shinkai, H. (2003) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2003.08.002 · Cited by 79
Lysophospholipids Enhance Matrix Metalloproteinase-2 Expression in Human Endothelial Cells
Wu, W. T., Chen, C., Lin, C. I., Chen, J. H., & Lee, H. (2005) · Endocrinology · doi:10.1210/en.2004-1654 · Cited by 76
Demidova‐Rice, T. N., Geevarghese, A., & Herman, I. M. (2010) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2010.00642.x · Cited by 76
Integrin-mediated regulation of epidermal wound functions
DiPersio, C. M., Zheng, R., Kenney, J., & Water, L. V. D. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2446-2 · Cited by 76
“Moreover, keratinocyte α3β1 promotes expression of MMP-9 (Iyer et al. 2005; Lamar et al. 2008), which has pro-angiogenic functions in wound healing and other tissue remodeling processes (Bergers et al. 2000; Hattori et al. 2009; McCawley and Matrisian 2001; Yu and Stamenkovic 2000).”
Ogawa, T., Takayama, K., Takakura, N., Kitano, S., & Ueno, H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700478 · Cited by 76
Epithelial-stromal interactions and tumor progression: meeting summary and future directions.
Matrisian, L. M., Cunha, G. R., & Mohla, S. (2001) · PubMed · Cited by 80
Fowlkes, J. L., & Winkler, M. K. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00005-9 · Cited by 76
Signaling Required for Blood Vessel Maintenance: Molecular Basis and Pathological Manifestations
Murakami, M. (2011) · International Journal of Vascular Medicine · doi:10.1155/2012/293641 · Cited by 77
Li, Y., Hoffman, M. D., & Benoit, D. S. W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120535 · Cited by 74
Park, S. U., Kim, T. H., Kim, S. H., You, S., & Jung, Y. (2021) · Cancers · doi:10.3390/cancers13163930 · Cited by 76
Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma.
Rojiani, M. V., Alidina, J., Esposito, N., & Rojiani, A. M. (2010) · Europe PMC (PubMed Central) · Cited by 75
TGF-β1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway
Sinpitaksakul, S. N., Pimkhaokham, A., Sanchavanakit, N., & Pavasant, P. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.128 · Cited by 75
Devy, L., & Dransfield, D. T. (2010) · Biochemistry Research International · doi:10.1155/2011/191670 · Cited by 75
Hoffmann, S., He, S., Ehren, M., Ryan, S. J., Wiedemann, P., & Hinton, D. R. (2006) · Retina · doi:10.1097/01.iae.0000238549.74626.33 · Cited by 75
Anti-angiogenic gene therapy of cancer: Current status and future prospects
Persano, L., Crescenzi, M., & Indraccolo, S. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.005 · Cited by 75
Better vascular engraftment and function in pancreatic islets transplanted without prior culture
Olsson, R. F., & Carlsson, P. (2005) · Diabetologia · doi:10.1007/s00125-004-1650-x · Cited by 75
A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Xu, X., Xiao, L., Xiao, P., Yang, S., Chen, G., Liu, F., Kanwar, Y. S., & Sun, L. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140716092052 · Cited by 74
Zijlstra, A., Seandel, M., Kupriyanova, T. A., Partridge, J. J., Madsen, M. A., Hahn-Dantona, E. A., Quigley, J. P., & Deryugina, E. I. (2005) · Blood · doi:10.1182/blood-2005-04-1458 · Cited by 76
Limaye, A. R., Clark, V., Soldevila‐Pico, C., Morelli, G., Suman, A., Firpi, R. J., Nelson, D. R., & Cabrera, R. (2012) · Hepatology Research · doi:10.1111/hepr.12019 · Cited by 75
Tauro, M., & Lynch, C. C. (2018) · Cancers · doi:10.3390/cancers10060185 · Cited by 77
“MMP-9 Gelatinase-B Collagens (IV, V, VII, X, and XIV), gelatin, aggrecan, elastin, plasminogen, MBP, and IL-1β ECM processing, bone resorption and remodeling, regulation of VEGFA bioavailability, and angiogenesis promotion [10,11]”
BackgroundCell and tissue responses to genotoxic stress
Coates, P. J., Lorimore, S. A., & Wright, E. G. (2005) · The Journal of Pathology · doi:10.1002/path.1701 · Cited by 77
Zhao, J., Xu, L., Jin, D., Xin, Y., Tian, L., Wang, T., Zhao, D., Wang, Z., & Wang, J. (2022) · Biomolecules · doi:10.3390/biom12101410 · Cited by 77
Luteolin inhibits matrix metalloproteinase 9 and 2 in azoxymethane-induced colon carcinogenesis
Pandurangan, A. K., Dharmalingam, P., Sadagopan, S., & Ganapasam, S. (2014) · Human & Experimental Toxicology · doi:10.1177/0960327114522502 · Cited by 74
Progression of Ocular Melanoma Metastasis to the Liver
Grossniklaus, H. E. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2547 · Cited by 74
Zuo, J., Ishikawa, T., Boutros, S., Xiao, Z., Humtsoe, J. O., & Kramer, R. H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0354 · Cited by 76
c-mycin the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo
He, C., Hu, H., Braren, R., Fong, S.-Y., Trumpp, A., Carlson, T. R., & Wang, R. A. (2008) · Development · doi:10.1242/dev.020131 · Cited by 74
The Tumor Microenvironment: Key to Early Detection
Ariztia, E. V., Lee, C. J., Gogoi, R. P., & Fishman, D. A. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600778836 · Cited by 71
Tumor-Associated Macrophages and Dendritic Cells as Prototypic Type II Polarized Myeloid Populations
Mantovani, A., Schioppa, T., Biswas, S. K., Marchesi, F., Allavena, P., & Sica, A. (2003) · Tumori Journal · doi:10.1177/030089160308900501 · Cited by 73
One microenvironment does not fit all: heterogeneity beyond cancer cells
Kim, I. S., & Zhang, X. H.-F. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9643-z · Cited by 75
“discovered in a RIP1-tag2 model of pancreatic islet carcinoma that MMP9 contributes to angiogenic switch through liberating angiogenesis inducer VEGF sequestered in normal and hyperplastic pancreatic islets [202].”
Background
Metadata
- Authors
- Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D.
- Affiliations
- University of California, San Francisco (US)
- Hope Heart Institute (US)
- Kyoto University (JP)
- Harold C. Simmons Comprehensive Cancer Center (US)
- RIKEN Center for Brain Science (JP)
- Corresponding author
- Hanahan, Douglas
- Venue
- Nature Cell Biology
- Published
- 2000-09-20
- Volume
- 2
- Issue
- 10
- Pages
- 737-744
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- PMC
- PMC2852586
- OpenAlex
- W1574172480
- Cited by
- 2,797
- References
- 45
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 76 · 2023: 74 · 2022: 96 · 2021: 90 · 2020: 92 · 2019: 88 · 2018: 82 · 2017: 107 · 2016: 110 · 2015: 98 · 2014: 133 · 2013: 140 · 2012: 137
- FWCI
- 36.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- MMP-9, angiogenic switch, vascular endothelial growth factor, VEGF signaling, MMP-2, urokinase, tumor angiogenesis, tumor growth, matrix metalloproteinase inhibitors, SU5416, transgenic mice
- MeSH terms
- Acetamides, Animals, Cell Transformation, Neoplastic, Genes, Switch, Islets of Langerhans, Lymphokines, Mice, Transgenic, Neovascularization, Pathologic, Pancreatic Neoplasms, Tissue Distribution, Signal Transduction, Endothelial Growth Factors, Receptors, Growth Factor, Matrix Metalloproteinase 9, Receptor Protein-Tyrosine Kinases, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
